Iovance Biotherapeutics, Inc.
NASDAQ: IOVA0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Frederick G. Vogt
- Employees
- 838
- Headquarters
- San Carlos, United States
- IPO year
- 2010
- Market cap
- $1.5B
- Website
- https://www.iovance.com
Loading IOVA…
Loading profile data…Frequently asked questions about IOVA
What does Iovance Biotherapeutics, Inc. (IOVA) do?
Iovance Biotherapeutics, Inc., a biotechnology firm currently in the clinical development stage, is committed to discovering and bringing to market cancer immunotherapy solutions. Its core mission involves leveraging the patient's own immune system to effectively combat and eradicate cancerous cells. The company is presently conducting six Phase...
Where does IOVA trade?
Iovance Biotherapeutics, Inc. (IOVA) trades on the NASDAQ Global Market.
What sector is IOVA in?
Iovance Biotherapeutics, Inc. (IOVA) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Iovance Biotherapeutics, Inc.?
Frederick G. Vogt is the chief executive officer of Iovance Biotherapeutics, Inc. (IOVA).
Where is Iovance Biotherapeutics, Inc. headquartered?
Iovance Biotherapeutics, Inc. is headquartered in United States.
Does IOVA pay a dividend?
Iovance Biotherapeutics, Inc. (IOVA) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did IOVA go public?
Iovance Biotherapeutics, Inc. (IOVA) completed its initial public offering in 2010.